Exelixis's Zanubrutinib Fails to Meet Primary Endpoint in Phase 3 Colorectal Cancer Trial
1. Academic Background and Data Analysis of Subgroup Clinical Trial Failure
Exelixis announced that its Phase 3 trial (STELLAR-303) evaluating zanubrutinib in combination with atezolizumab (brand name: Tecentriq) for patients with colorectal cancer failed to meet the primary endpoint of overall survival (OS) in the subgroup of patients without active liver metastases. The final analysis showed that the combination therapy achieved a median survival of 15.9 months, compared to 12.7 months for the control group, Bayer's Stivarga (regorafenib), demonstrating a numerical improvement. However, it did not reach statistical significance. The hazard ratio (HR) was 0.83 (95% confidence interval: 0.66 to 1.05), and the p-value was 0.1185, failing to definitively prove the clinical hypothesis. The medical community believes that this may be due to the tumor microenvironment (TME) in colorectal cancer patients exhibiting different immune responses and anti-angiogenic effects depending on the presence of liver metastases.
2. FDA Approval Prospects Based on Success in the Overall Patient Population
Despite the failure in this subgroup analysis, the trial has already demonstrated statistically significant improvement in overall survival (OS) in the overall ITT (Intention-To-Treat) patient population. This successful data was published in the international journal 'The Lancet' and will be presented in detail at the European Society for Medical Oncology (ESMO) 2025. Based on the data from the overall patient population, Exelixis submitted a New Drug Application (NDA) to the FDA in February 2026, which was accepted for review. The final review date under the Prescription Drug User Fee Act (PDUFA) is scheduled for December 3, 2026. Industry analysts believe that while the primary endpoint data for the overall patient population is strong, the failure in the subgroup may limit the scope of approval (labeling).
3. Risk of Cabometyx Patent Expiration and Revenue Gap
Zanubrutinib has been considered a key next-generation pipeline asset for Exelixis, poised to succeed its blockbuster targeted therapy, Cabometyx (cabozantinib), after its patent expiration. In 2025, Cabometyx generated approximately $2.32 billion in annual revenue, supporting the majority of the company's overall revenue. However, it is expected to face patent challenges and generic competition around 2030. Zanubrutinib is a strategically designed asset with a shortened half-life to improve patient convenience and tolerability, making it suitable for combination therapy. The disappointing results in the colorectal cancer trial may hinder the company's efforts to establish a commercial base for a new drug before the stable revenue stream from Cabometyx ends.
4. Increasing Competition in the Colorectal Cancer Market and Commercial Value Assessment
Currently, the global third-line colorectal cancer market is dominated by Bayer's Stivarga and Takeda's Fruzaqla (fruquintinib), which is gaining market share. Fruzaqla has already demonstrated excellent clinical efficacy in its Phase 3 trial (FRESCO-2). Therefore, the latecomer, zanubrutinib, needed to demonstrate a clear survival advantage through synergistic effects with immune checkpoint inhibitors. The failure in this subgroup analysis may diminish the commercial value of the zanubrutinib combination therapy and pose a challenge in securing market share in the future. Ultimately, this event suggests that Exelixis needs to further invest in additional clinical data or expand indications to maintain its leadership in the oncology market.
The failure of Exelixis's (EXEL) Phase 3 trial (STELLAR-303) subgroup analysis (median survival of 15.9 months vs. 12.7 months, hazard ratio of 0.83, p=0.1185) introduces uncertainty into the regulatory approval pathway for zanubrutinib, which aims to enter the third-line colorectal cancer market. With the FDA's PDUFA date set for December 3, 2026, the lack of efficacy in the subgroup may lead to label restrictions or approval delays, posing a short-term regulatory risk. This impacts the company's long-term strategy to prepare for the patent expiration (expected around 2030-2031) of Cabometyx, its key revenue driver, which generated $2.32 billion in annual revenue in 2025. In a market where competitors like Takeda's Fruzaqla (fruquintinib) and Bayer's Stivarga (regorafenib) are established, the commercial differentiation of zanubrutinib may be weakened. From a research perspective, this case highlights the limitations of combining a TKI targeted therapy with an immune checkpoint inhibitor such as atezolizumab (Tecentriq) in overcoming the complex microenvironment of colorectal cancer.